Port Washington, New York (PRWEB) December 30, 2011
The U.S. Judicial Panel on Multidistrict Litigation (JPML) has consolidated all pending federal Actos bladder cancer lawsuits in a multidistrict litigation, and has assigned the docket to the Honorable Judge Rebecca F. Doherty, U.S. District Court for the Western District of Louisiana (MDL 2299). In a motion filed with the JPML earlier this year, the national law firm of Parker Waichman Alonso LLP supported the consolidation of the Actos lawsuits, as well as their transfer to Judge Doherty.
According to a Transfer Order issued by the JPML on December 29, 2011, more than 100 Actos lawsuits will be transferred to Judge Doherty, as stated in NewsInferno.com. In its Transfer Order, the Panel noted that “centralization in the Western District of Louisiana permits the Panel to assign the litigation to an experienced judge who sits in a district in which no other multidistrict litigation is pending.”
Actos, known generically as pioglitazone, was launched in 1999 by Takeda Pharmaceuticals America Inc. and Eli Lilly and Co., as a treatment for Type II diabetes. Actos, now one of Takeda's top-selling drugs, had global sales last year of $4.8 billion and accounts for 27 percent of the company's revenue. Plaintiffs in Actos bladder cancer lawsuits allege that patients who ingested the drug for more than a year were at increased risks for developing bladder cancer and other injuries, including kidney cancer. Such lawsuits further allege that Defendants promoted Actos as a safe and effective treatment for Type II diabetes, even though they knew or should have known that taking Actos for longer than 12 months increased the risk of bladder cancer.
(fda.gov/Drugs/DrugSafety/ucm259150.htm , bloomberg.com/news/2011-12-01/takeda-may-face-10-000-u-s-suits-over-actos-cancer-claims.html)
On September 17, 2010, the U.S. Food & Drug Administration (FDA) announced it had begun an Actos safety review after preliminary data from a study conducted by Kaiser Permanente demonstrated that the risk of bladder cancer increases with increasing dose and duration of Actos use, reaching statistical significance after 24 months. On June 15, 2011, the FDA issued another safety communication stating that use of Actos for more than one year may be associated with an increased risk of bladder cancer. When compared to persons never treated with Actos, taking the drug for more than 12 months was associated with a 40 percent increase in the risk of developing bladder cancer, the agency said. The FDA mandated that new information about this risk be added to the "Warnings and Precautions" section of the Actos label.
Parker Waichman Alonso LLP continues to offer free legal consultations to victims of Actos. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting the firm's Actos injury page at http://www.yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).
For more information regarding Actos bladder cancer lawsuits and Parker Waichman Alonso LLP, please visit: yourlawyer.com or call 1-800-LAW-INFO (1-800-529-4636).
Contact: Parker Waichman Alonso LLP